WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

GC Wellbeing secures rights to next-gen fat-dissolving injection

GC Wellbeing said Monday it has signed a license-in agreement with Israeli biotech company Raziel Therapeutics to commercialize its next-generation localized fa

Raccontata dakoreatimes.co.krkoreaherald.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
koreaherald.comStai leggendo2 g fa

GC Wellbeing secures rights to next-gen fat-dissolving injection

GC Wellbeing said Monday it has signed a license-in agreement with Israeli biotech company Raziel Therapeutics to commercialize its next-generation localized fa

originale
koreatimes.co.kr5 g fa

GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market - The Korea Times

Korean health care company GC Wellbeing signed a strategic partnership agreement with U.S.-Israeli biotechnology firm Raziel Therapeutics to commer...

Leggi questa versione → originale

Timeline cronologica

  1. venerdì 26 giugno 2026·koreatimes.co.kr

    GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market - The Korea Times

    Korean health care company GC Wellbeing signed a strategic partnership agreement with U.S.-Israeli biotechnology firm Raziel Therapeutics to commer...

  2. lunedì 29 giugno 2026·koreaherald.com

    GC Wellbeing secures rights to next-gen fat-dissolving injection

    GC Wellbeing said Monday it has signed a license-in agreement with Israeli biotech company Raziel Therapeutics to commercialize its next-generation localized fa